<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896907</url>
  </required_header>
  <id_info>
    <org_study_id>16D.347</org_study_id>
    <nct_id>NCT02896907</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Pilot Study of Intravenous Ascorbic Acid and Folfirinox in the Treatment of Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the side effects of ascorbic acid and combination
      chemotherapy in treating patients with pancreatic cancer that has spread to other places in
      the body, has come back, or cannot be removed by surgery. Nutrients found in food and dietary
      supplements, such as ascorbic acid, may improve the tolerability of chemotherapy regimens.
      Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, and oxaliplatin,
      work in different ways to stop the growth of tumor cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and
      combination chemotherapy may work better in treating patients with pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine safety of intravenous ascorbic acid in combination with fluorouracil,
      irinotecan hydrochloride, leucovorin calcium, and oxaliplatin (FOLFIRINOX) as defined by
      Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 in patients with advanced
      pancreatic cancer.

      SECONDARY OBJECTIVES:

      I. To test feasibility of collecting quality of life (QOL), patient reported outcomes (PRO)
      data and correlative studies on patients with advanced pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as Determined by CTCAE Version 4.03</measure>
    <time_frame>Up to 28 days after the last treatment</time_frame>
    <description>After 4 patients are enrolled on the study and receive at least one dose of intravenous ascorbic acid, the data will be reviewed. If 2 out of the 4 cannot complete 2 courses of FOLFIRINOX then the study will be halted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30</measure>
    <time_frame>Baseline to up to 28 days after the last treatment</time_frame>
    <description>Change in quality of life over the six measurement times will be modeled using mixed effects linear regression to account for correlation among repeated measurements from the same subjects. Average change in QoL from baseline to follow-up will be computed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Recurrent Pancreatic Carcinoma</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>61825-94-3</other_name>
    <other_name>[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum</other_name>
    <other_name>[Sp-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>trans-l diaminocyclohexane oxalatoplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>136572-09-3</other_name>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Camptothecin 11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>1492-18-8</other_name>
    <other_name>3590</other_name>
    <other_name>5-Formyl Tetrahydrofolate</other_name>
    <other_name>5-Formyl-5,6,7,8-tetrahydrofolic Acid</other_name>
    <other_name>5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid</other_name>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1)</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folix</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>19893</other_name>
    <other_name>2,4-Dioxo-5-fluoropyrimidine</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLFIRINOX, ascorbic acid)</arm_group_label>
    <other_name>2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one</other_name>
    <other_name>33832</other_name>
    <other_name>50-81-7</other_name>
    <other_name>Asorbicap</other_name>
    <other_name>C Vitamin</other_name>
    <other_name>C-Long</other_name>
    <other_name>Ce-Vi-Sol</other_name>
    <other_name>Cecon</other_name>
    <other_name>Cenolate</other_name>
    <other_name>L-Ascorbic Acid</other_name>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving informed consent

          -  Histological diagnosis of adenocarcinoma of the pancreas

          -  Stage IV or recurrent pancreatic cancer by imaging

          -  Locally advanced unresectable pancreatic cancer by National Comprehensive Cancer
             Network (NCCN) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

          -  No prior treatment for metastatic disease (prior neo-adjuvant or adjuvant
             chemotherapy, except FOLFIRINOX, chemoradiation or radiation allowed)

          -  White blood count &gt;= 3000

          -  Platelets &gt;= 100,000

          -  Total bilirubin =&lt; 1.5 mg/dl

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 5 X upper limit
             of normal (ULN)

          -  Creatinine &lt; 1.5 mg/dL

          -  Glucose-6-phosphatase deficiency (G6PD) level of 5-14 units/g hemoglobin (Hgb) or
             within institutional standard parameters

          -  All subjects of child producing potential must agree to use contraception or avoidance
             of pregnancy measures while enrolled on study

        Exclusion Criteria:

          -  Other pancreatic cancer histology (islet cell, acinar, neuroendocrine tumors)

          -  Resectable pancreatic cancer

          -  Prior neoadjuvant FOLFIRINOX

          -  Pregnant or lactating females

          -  No clinical ascites (mild ascites on scans permissible)

          -  Central nervous system (CNS) metastasis

          -  Known congestive heart failure, significant ventricular arrhythmias, cirrhosis, grade
             4/5 chronic kidney disease, uncontrolled diabetes

          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic
             therapy

          -  Peripheral neuropathy grade 2 or greater

          -  Any condition, psychiatric or otherwise, that would preclude informed consent,
             consistent follow-up or compliance with any aspect of the study (e.g., untreated
             schizophrenia or other significant cognitive impairment, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Posey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <results_first_submitted>October 29, 2019</results_first_submitted>
  <results_first_submitted_qc>January 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
    <mesh_term>Formyltetrahydrofolates</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02896907/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (FOLFIRINOX, Ascorbic Acid)</title>
          <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Oxaliplatin: Given IV
Irinotecan Hydrochloride: Given IV
Leucovorin Calcium: Given IV
Fluorouracil: Given IV
Ascorbic Acid: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (FOLFIRINOX, Ascorbic Acid)</title>
          <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Oxaliplatin: Given IV
Irinotecan Hydrochloride: Given IV
Leucovorin Calcium: Given IV
Fluorouracil: Given IV
Ascorbic Acid: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as Determined by CTCAE Version 4.03</title>
        <description>After 4 patients are enrolled on the study and receive at least one dose of intravenous ascorbic acid, the data will be reviewed. If 2 out of the 4 cannot complete 2 courses of FOLFIRINOX then the study will be halted.</description>
        <time_frame>Up to 28 days after the last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLFIRINOX, Ascorbic Acid)</title>
            <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Oxaliplatin: Given IV
Irinotecan Hydrochloride: Given IV
Leucovorin Calcium: Given IV
Fluorouracil: Given IV
Ascorbic Acid: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as Determined by CTCAE Version 4.03</title>
          <description>After 4 patients are enrolled on the study and receive at least one dose of intravenous ascorbic acid, the data will be reviewed. If 2 out of the 4 cannot complete 2 courses of FOLFIRINOX then the study will be halted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 4 adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 5 adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3 adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Serious Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30</title>
        <description>Change in quality of life over the six measurement times will be modeled using mixed effects linear regression to account for correlation among repeated measurements from the same subjects. Average change in QoL from baseline to follow-up will be computed.</description>
        <time_frame>Baseline to up to 28 days after the last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLFIRINOX, Ascorbic Acid)</title>
            <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Oxaliplatin: Given IV
Irinotecan Hydrochloride: Given IV
Leucovorin Calcium: Given IV
Fluorouracil: Given IV
Ascorbic Acid: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30</title>
          <description>Change in quality of life over the six measurement times will be modeled using mixed effects linear regression to account for correlation among repeated measurements from the same subjects. Average change in QoL from baseline to follow-up will be computed.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Due to the small number of participants, quality of life assessments were not looked at quantitatively. Attempts have been made to obtain additional information from the investigator but no information has been provided.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline through 30 days after completing treatment; an average of 4 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (FOLFIRINOX, Ascorbic Acid)</title>
          <description>Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Oxaliplatin: Given IV
Irinotecan Hydrochloride: Given IV
Leucovorin Calcium: Given IV
Fluorouracil: Given IV
Ascorbic Acid: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Posey</name_or_title>
      <organization>Sidney Kimmel Cancer Center at Thomas Jefferson University</organization>
      <phone>215-503-6442</phone>
      <email>James.Posey@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

